## Andrea Haitel

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2191923/publications.pdf

Version: 2024-02-01

331259 377514 1,348 58 21 34 h-index citations g-index papers 58 58 58 2369 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. European Urology, 2021, 79, 480-488.	0.9	198
2	STAT3 regulated ARF expression suppresses prostate cancer metastasis. Nature Communications, 2015, 6, 7736.	5.8	136
3	Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma. Journal of Urology, 2017, 198, 1253-1262.	0.2	58
4	The preoperative prognostic nutritional index is an independent predictor of survival in patients with renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 68.e1-68.e7.	0.8	56
5	Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1166-1171.	0.8	42
6	A urinary microRNA (miR) signature for diagnosis of bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e1-531.e8.	0.8	41
7	Multi-institutional Validation of the Predictive Value of Ki-67 in Patients with High Grade Urothelial Carcinoma of the Upper Urinary Tract. Journal of Urology, 2015, 193, 1486-1493.	0.2	38
8	<i> <scp>STAT</scp> 3 </i> à€dependent analysis reveals <i> <scp>PDK</scp> 4 </i> as independent predictor of recurrence in prostate cancer. Molecular Systems Biology, 2020, 16, e9247.	3.2	38
9	Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. World Journal of Urology, 2017, 35, 121-130.	1.2	37
10	Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. Molecular Carcinogenesis, 2016, 55, 1458-1466.	1.3	33
11	HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World Journal of Urology, 2017, 35, 251-259.	1.2	33
12	Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. Clinical Genitourinary Cancer, 2017, 15, e267-e273.	0.9	33
13	HSP90 is necessary for the ACK1-dependent phosphorylation of STAT1 and STAT3. Cellular Signalling, 2017, 39, 9-17.	1.7	32
14	Prognostic role of N-cadherin expression in patients with non–muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 264-271.	0.8	30
15	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	3.3	30
16	Carbonic Anhydrase IX as a Diagnostic Urinary Marker for Urothelial Bladder Cancer. European Urology, 2015, 68, 552-554.	0.9	29
17	Intraductal carcinoma of prostate reporting practice: a survey of expert European uropathologists. Journal of Clinical Pathology, 2016, 69, 852-857.	1.0	29
18	Quantitative Apparent Diffusion Coefficient Measurements Obtained by 3-Tesla MRI Are Correlated with Biomarkers of Bladder Cancer Proliferative Activity. PLoS ONE, 2014, 9, e106866.	1.1	29

#	Article	IF	CITATIONS
19	Insulin-like Growth Factor Messenger RNA-binding Protein 3 Expression Helps Prognostication in Patients with Upper Tract Urothelial Carcinoma. European Urology, 2014, 66, 379-385.	0.9	27
20	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	0.8	27
21	Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 113-120.	1.2	22
22	Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice. BJU International, 2018, 121, 84-92.	1.3	22
23	Cancer stage and pack-years, but not p16 or HPV, are relevant for survival in hypopharyngeal and laryngeal squamous cell carcinomas. European Archives of Oto-Rhino-Laryngology, 2018, 275, 1837-1843.	0.8	22
24	Evaluation of the Prognostic Significance of Altered Mammalian Target of Rapamycin Pathway Biomarkers in Upper Tract Urothelial Carcinoma. Urology, 2014, 84, 1134-1140.	0.5	18
25	The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 533.e1-533.e10.	0.8	17
26	Thyroid and androgen receptor signaling are antagonized by μ rystallin in prostate cancer. International Journal of Cancer, 2021, 148, 731-747.	2.3	17
27	Altered Expression of the Transcription Factor Forkhead Box A1 (FOXA1) Is Associated With Poor Prognosis in Urothelial Carcinoma of the Upper Urinary Tract. Urology, 2016, 94, 314.e1-314.e7.	0.5	16
28	Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: A multi-institutional study. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 495.e15-495.e22.	0.8	15
29	Serum Adiponectin Predicts Cancer-specific Survival of Patients with Renal Cell Carcinoma. European Urology Focus, 2016, 2, 197-203.	1.6	15
30	Dynamic Prognostication Using Conditional Recurrence and Progression Estimates for Patients with Nonmuscle Invasive Bladder Cancer. Journal of Urology, 2016, 196, 46-51.	0.2	13
31	Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, e73-e78.	0.9	13
32	Associations Between Presenting Symptoms, Clinicopathological Parameters, and Prognosis in a Contemporary Series of Patients With Renal Cell Carcinoma. Korean Journal of Urology, 2014, 55, 505.	1.2	12
33	Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2017, 35, 1073-1080.	1.2	12
34	Impact of the Level of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. Bladder Cancer, 2017, 3, 161-169.	0.2	12
35	Discovery of Molecular DNA Methylation-Based Biomarkers through Genome-Wide Analysis of Response Patterns to BCG for Bladder Cancer. Cells, 2020, 9, 1839.	1.8	11
36	Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound. European Urology, 2022, 82, 261-270.	0.9	11

#	Article	IF	CITATIONS
37	Evaluation of tyrosine kinase receptors in brain metastases of clear cell renal cell carcinoma reveals <scp>cM</scp> et as a negative prognostic factor. Histopathology, 2015, 67, 799-805.	1.6	10
38	Association of super-extended lymphadenectomy at radical cystectomy with perioperative complications and re-hospitalization. World Journal of Urology, 2020, 38, 121-128.	1.2	10
39	Visibility of significant prostate cancer on multiparametric magnetic resonance imaging (MRI)—do we still need contrast media?. European Radiology, 2021, 31, 3754-3764.	2.3	10
40	Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study. World Journal of Urology, 2019, 37, 2419-2427.	1.2	9
41	Histopathology and prognosis of de novo bladder tumors following solid organ transplantation. World Journal of Urology, 2015, 33, 2087-2093.	1.2	8
42	HER2 and TOP2A Gene Amplification and Protein Expression in Upper Tract Urothelial Carcinomas. Pathology and Oncology Research, 2018, 24, 575-581.	0.9	8
43	The Phenotypic Characterization of the Human Renal Mononuclear Phagocytes Reveal a Co-Ordinated Response to Injury. PLoS ONE, 2016, 11, e0151674.	1.1	7
44	PTRF independently predicts progression and survival in multiracial upper tract urothelial carcinoma following radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 496-505.	0.8	6
45	The prognostic impact of tumour NSD2 expression in advanced prostate cancer. Biomarkers, 2020, 25, 268-273.	0.9	6
46	Comparison of Permethrin-Based Treatment Strategies against Scabies in Infants and Young Children. Journal of Pediatrics, 2022, 245, 184-189.	0.9	6
47	Frequency and Prognostic Value of PTEN Loss in Patients with Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy. Journal of Urology, 2017, 198, 1269-1277.	0.2	5
48	Prognostic role of the urokinase plasminogen activator (uPA) system in patients with nonmuscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 774-783.	0.8	5
49	Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. World Journal of Urology, 2016, 34, 1155-1161.	1.2	4
50	Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 356-362.	0.8	4
51	Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 343.e1-343.e8.	0.8	4
52	Urinary expression of genes involved in DNA methylation and histone modification for diagnosis of bladder cancer in patients with asymptomatic microscopic haematuria. Oncology Letters, 2019, 18, 57-62.	0.8	4
53	The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC). Urologic Oncology: Seminars and Original Investigations, 2020, 38, 423-432.	0.8	4
54	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non–muscle-invasive Bladder Cancer Spectrum. European Urology Focus, 2022, , .	1.6	4

## Andrea Haitel

#	Article	IF	CITATIONS
55	Prevalence and Prognostic Value of the Polymorphic Variant 1245A>C of HSD3B1 in Castration-resistant Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 389-394.	0.9	3
56	Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. European Urology Focus, 2019, 5, 97-103.	1.6	3
57	More than ancillary records: clinical implications of renal pathology examination in tumor nephrectomy specimens. Journal of Nephrology, 2021, 34, 1833-1844.	0.9	2
58	The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 685.e17-685.e25.	0.8	2